Author

Karl Marquez

Observed name: Karl S. Marquez

Institution: Poseida Therapeutics (United States)

Observed institution: Poseida Therapeutics (United States)

ORCID: 0000-0003-1511-4484

Observed ORCID: 0000-0003-1511-4484

OpenAlex ID: A5088486709

Cas-CLOVER is a novel high-fidelity nuclease for safe and robust generation of TSCM-enriched allogeneic CAR-T cells

2022 · Blair B. Madison, Deepak Patil, et al. · Molecular Therapy — Nucleic Acids · 62

TSCM-predominant allogeneic anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trial

2025 · Hubert Tseng, Bhagirathbhai Dholaria, et al. · Nature Communications · 10

Memory Phenotype in Allogeneic Anti-BCMA CAR-T Cell Therapy (P-BCMA-ALLO1) Correlates with In Vivo Tumor Control

2021 · Hubert Tseng, Yan Zhang, et al. · Blood · 5

Cas-CLOVER is a novel high-fidelity nuclease for safe and robust generation of TSCM-enriched allogeneic CAR-T cells

2022 · Blair B. Madison, Deepak Patil, et al. · Molecular Therapy — Nucleic Acids · 2

147 Memory phenotype in allogeneic anti-BCMA CAR-T cell therapy (P-BCMA-ALLO1) correlates with in vivo tumor control

2021 · Hubert Tseng, Yan Zhang, et al. · Journal for ImmunoTherapy of Cancer · 1

310 Multi-antigen targeting with CAR and TCR co-expression in allogeneic cell therapy for solid tumors

2024 · Sergio M Quinones Parra, Lu Yao, et al. · Journal for ImmunoTherapy of Cancer

A Tumor-Bearing Murine Xenograft Model As a Bioassay for Assessing CAR-T Product Potency Shows Positive Predictive Value for Clinical Performance

2023 · Stacey A Cranert, Hubert Tseng, et al. · Blood

Works count: 7

Citation count: 80

H-index: 3

I10-index: 2